Published in J Biol Chem on June 27, 2006
A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2008) 2.93
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A (2007) 2.02
Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87
Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A (2007) 1.76
Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A (2010) 1.36
Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol (2010) 1.33
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33
Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity. J Virol (2007) 1.25
Peptides in the treatment of AIDS. Curr Opin Struct Biol (2009) 1.21
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol (2008) 1.20
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog (2009) 1.15
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem (2008) 1.14
Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog (2010) 1.14
Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics. Virology (2008) 1.11
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11
Viral entry inhibitors targeted to the membrane site of action. J Virol (2010) 1.10
A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol (2007) 1.05
HIV entry: a game of hide-and-fuse? Curr Opin Virol (2013) 1.04
Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: stability and pH effects. Protein Sci (2011) 1.02
Kinetic dependence of paramyxovirus entry inhibition. J Virol (2009) 1.00
Time frames for neutralization during the human immunodeficiency virus type 1 entry phase, as monitored in synchronously infected cell cultures. J Virol (2007) 0.93
Peptide mimic of the HIV envelope gp120-gp41 interface. J Mol Biol (2007) 0.90
Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J Virol (2009) 0.90
Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. Bioconjug Chem (2012) 0.88
Protease-resistant peptide design-empowering nature's fragile warriors against HIV. Biopolymers (2012) 0.86
Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors. Viruses (2012) 0.86
Kinetically coupled folding of a single HIV-1 glycoprotein 41 complex in viral membrane fusion and inhibition. Proc Natl Acad Sci U S A (2015) 0.84
Amphipathic properties of HIV-1 gp41 fusion inhibitors. Curr Top Med Chem (2011) 0.84
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. PLoS Pathog (2016) 0.82
SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins. J Biol Chem (2017) 0.81
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol (2014) 0.81
Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41. J Med Chem (2014) 0.81
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. J Biol Chem (2017) 0.81
Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways. J Biol Chem (2012) 0.80
Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum. PLoS Pathog (2013) 0.80
Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination. FASEB J (2011) 0.78
HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations. Can J Infect Dis Med Microbiol (2013) 0.76
Enhanced potency of bivalent small molecule gp41 inhibitors. Bioorg Med Chem (2016) 0.75
Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. PLoS Comput Biol (2014) 0.75
Site-specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates rather than Binding Affinity. Bioconjug Chem (2016) 0.75
How entry inhibitors synergize to fight HIV. J Biol Chem (2017) 0.75
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog (2009) 1.15
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem (2008) 1.14
Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS One (2008) 1.11
Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. J Immunol Methods (2008) 0.99
Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitors. Biomacromolecules (2012) 0.94
A human monoclonal antibody that binds serotype A botulinum neurotoxin. Hybridoma (Larchmt) (2008) 0.93
Nucleoporin Nup50 stabilizes closed conformation of armadillo repeat 10 in importin α5. J Biol Chem (2011) 0.91
C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells. J Invest Dermatol (2007) 0.82
Clinical pharmacology of human growth hormone and its secretagogues. Curr Drug Targets Immune Endocr Metabol Disord (2002) 0.82